AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Expedition Therapeutics raised $115M in Series B funding, led by General Atlantic. The firm will use the capital to advance its lead DPP1 inhibitor EXPD-101 through Phase 2 clinical development.
Amount Raised
$115 Million
Round Type
Series B
San FranciscoBiotechnologyHealth CareresearchInvestors
Description
Expedition Therapeutics, a San Francisco, CA-based clinical-stage biotechnology platform, raised $115M in Series B financing. The round was led by General Atlantic with participation from several investors. The funds will support the advancement of their lead DPP1 inhibitor EXPD-101 and expand their therapy pipeline. Their innovative platform targets neutrophil-driven diseases.
Fundz sees it the moment Expedition Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansExpedition Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.